Journal article
Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
Abstract
PURPOSE: This study was designed to evaluate the associations between angiogenesis gene polymorphisms and clinical outcome in ovarian cancer patients treated with low-dose cyclophosphamide and bevacizumab.
EXPERIMENTAL DESIGN: Seventy recurrent/metastatic epithelial ovarian cancer patients were enrolled in a phase II clinical trial. Genomic DNA was available from 53 blood samples. Polymorphisms were analyzed using the PCR-RFLP protocol. A 5' …
Authors
Schultheis AM; Lurje G; Rhodes KE; Zhang W; Yang D; Garcia AA; Morgan R; Gandara D; Scudder S; Oza A
Journal
Clinical Cancer Research, Vol. 14, No. 22, pp. 7554–7563
Publisher
American Association for Cancer Research (AACR)
Publication Date
November 15, 2008
DOI
10.1158/1078-0432.ccr-08-0351
ISSN
1078-0432
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCyclophosphamideDisease-Free SurvivalDrug Resistance, NeoplasmFemaleHumansKaplan-Meier EstimateOvarian NeoplasmsPilot ProjectsPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthPolymorphism, Single Nucleotide